Imunon, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Imunon, Inc. (IMNN) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value of $13.20 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue · last filed 2026-03-31
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for the quarter ending 2014-03-31 was $8.00.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2024 was $13.20, a 186.96% increase from fiscal 2023.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2023 was $4.60, a 51.32% decline from fiscal 2022.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2022 was $9.45, a 71.62% decline from fiscal 2021.
- Imunon, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeitures, weighted average grant date fair value for fiscal 2021 was $33.30, a 39.62% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $13.20 10-K · filed 2026-03-31 | $0.88 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $4.60 10-K · filed 2025-02-27 | ||||
| 2022-12-31 | $9.45 10-K · filed 2024-03-28 | ||||
| 2021-12-31 | $33.30 10-K · filed 2023-03-30 | ||||
| 2020-12-31 | $23.85 10-K · filed 2022-03-31 | $1.59 10-K · filed 2021-03-19 | |||
| 2019-12-31 | $2.48 10-K · filed 2021-03-19 | ||||
| 2014-06-30 | $8.00 10-Q · filed 2014-08-07 | ||||
| 2014-03-31 | $8.00 10-Q · filed 2014-05-08 | ||||
| 2013-12-31 | $15.69 10-K · filed 2016-03-30 | ||||
| 2013-09-30 | $18.59 10-Q · filed 2013-11-12 | ||||
| 2013-06-30 | $4.13 10-Q · filed 2013-08-08 | ||||
| 2012-12-31 | $12.56 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | $2.86 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |